Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Erica J. Childs; Evelina Mocci; Daniele Campa; Paige M. Bracci; Steven Gallinger; Michael Goggins; Donghui Li; Rachel E. Neale; Sara H. Olson; Ghislaine Scelo; Laufey T. Amundadottir; William R. Bamlet; Maarten F. Bijlsma; Amanda Blackford; Michael Borges; Paul Brennan; Hermann Brenner; H. Bas Bueno-De-Mesquita; Federico Canzian; Gabriele Capurso; Giulia M. Cavestro; Kari G. Chaffee; Stephen J. Chanock; Sean P. Cleary; Michelle Cotterchio; Lenka Foretova; Charles Fuchs; Niccola Funel; Maria Gazouli; Manal Hassan; Joseph M. Herman; Ivana Holcatova; Elizabeth A. Holly; Robert N. Hoover; Rayjean J. Hung; Vladimir Janout; Timothy J. Key; Juozas Kupcinskas; Robert C. Kurtz; Stefano Landi; Lingeng Lu; Ewa Malecka-Panas; Andrea Mambrini; Beatrice Mohelnikova-Duchonova; John P. Neoptolemos; Ann L. Oberg; Irene Orlow; Claudio Pasquali; Raffaele Pezzilli; Cosmeri Rizzato; Amethyst Saldia; Aldo Scarpa; Rachael Z. Stolzenberg-Solomon; Oliver Strobel; Francesca Tavano; Yogesh K. Vashist; Pavel Vodicka; Brian M. Wolpin; Herbert Yu; Gloria M. Petersen; Harvey A. Risch; Alison P. Klein

doi:10.1038/ng.3341

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Erica J. Childs, Evelina Mocci, Daniele Campa, Paige M. Bracci, Steven Gallinger, Michael Goggins, Donghui Li, Rachel E. Neale, Sara H. Olson, Ghislaine Scelo, Laufey T. Amundadottir, William R. Bamlet, Maarten F. Bijlsma, Amanda Blackford, Michael Borges, Paul Brennan, Hermann Brenner, H. Bas Bueno-De-Mesquita, Federico Canzian, Gabriele CapursoGiulia M. Cavestro, Kari G. Chaffee, Stephen J. Chanock, Sean P. Cleary, Michelle Cotterchio, Lenka Foretova, Charles Fuchs, Niccola Funel, Maria Gazouli, Manal Hassan, Joseph M. Herman, Ivana Holcatova, Elizabeth A. Holly, Robert N. Hoover, Rayjean J. Hung, Vladimir Janout, Timothy J. Key, Juozas Kupcinskas, Robert C. Kurtz, Stefano Landi, Lingeng Lu, Ewa Malecka-Panas, Andrea Mambrini, Beatrice Mohelnikova-Duchonova, John P. Neoptolemos, Ann L. Oberg, Irene Orlow, Claudio Pasquali, Raffaele Pezzilli, Cosmeri Rizzato, Amethyst Saldia, Aldo Scarpa, Rachael Z. Stolzenberg-Solomon, Oliver Strobel, Francesca Tavano, Yogesh K. Vashist, Pavel Vodicka, Brian M. Wolpin, Herbert Yu, Gloria M. Petersen, Harvey A. Risch, Alison P. Klein

School of Medicine

Research output: Contribution to journal › Article › peer-review

148 Scopus citations

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased risk. To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 × 10-14), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 × 10-8) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 × 10-8). We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 × 10-9), a region with previous suggestive evidence in Han Chinese. We replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 (LINC-PINT), 16q23.1 (BCAR1) and 22q12.1 (ZNRF3). Our study identifies new loci associated with pancreatic cancer risk.

Original language	English (US)
Pages (from-to)	911-916
Number of pages	6
Journal	Nature genetics
Volume	47
Issue number	8
DOIs	https://doi.org/10.1038/ng.3341
State	Published - Aug 30 2015

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/ng.3341

Cite this

Childs, E. J., Mocci, E., Campa, D., Bracci, P. M., Gallinger, S., Goggins, M., Li, D., Neale, R. E., Olson, S. H., Scelo, G., Amundadottir, L. T., Bamlet, W. R., Bijlsma, M. F., Blackford, A., Borges, M., Brennan, P., Brenner, H., Bueno-De-Mesquita, H. B., Canzian, F., ... Klein, A. P. (2015). Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature genetics, 47(8), 911-916. https://doi.org/10.1038/ng.3341

Childs, EJ, Mocci, E, Campa, D, Bracci, PM, Gallinger, S, Goggins, M, Li, D, Neale, RE, Olson, SH, Scelo, G, Amundadottir, LT, Bamlet, WR, Bijlsma, MF, Blackford, A, Borges, M, Brennan, P, Brenner, H, Bueno-De-Mesquita, HB, Canzian, F, Capurso, G, Cavestro, GM, Chaffee, KG, Chanock, SJ, Cleary, SP, Cotterchio, M, Foretova, L, Fuchs, C, Funel, N, Gazouli, M, Hassan, M, Herman, JM, Holcatova, I, Holly, EA, Hoover, RN, Hung, RJ, Janout, V, Key, TJ, Kupcinskas, J, Kurtz, RC, Landi, S, Lu, L, Malecka-Panas, E, Mambrini, A, Mohelnikova-Duchonova, B, Neoptolemos, JP, Oberg, AL, Orlow, I, Pasquali, C, Pezzilli, R, Rizzato, C, Saldia, A, Scarpa, A, Stolzenberg-Solomon, RZ, Strobel, O, Tavano, F, Vashist, YK, Vodicka, P, Wolpin, BM, Yu, H, Petersen, GM, Risch, HA & Klein, AP 2015, 'Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer', Nature genetics, vol. 47, no. 8, pp. 911-916. https://doi.org/10.1038/ng.3341

@article{366172892d1f4814832adecb75d3e686,

title = "Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer",

abstract = "Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased risk. To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 × 10-14), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 × 10-8) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 × 10-8). We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 × 10-9), a region with previous suggestive evidence in Han Chinese. We replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 (LINC-PINT), 16q23.1 (BCAR1) and 22q12.1 (ZNRF3). Our study identifies new loci associated with pancreatic cancer risk.",

author = "Childs, {Erica J.} and Evelina Mocci and Daniele Campa and Bracci, {Paige M.} and Steven Gallinger and Michael Goggins and Donghui Li and Neale, {Rachel E.} and Olson, {Sara H.} and Ghislaine Scelo and Amundadottir, {Laufey T.} and Bamlet, {William R.} and Bijlsma, {Maarten F.} and Amanda Blackford and Michael Borges and Paul Brennan and Hermann Brenner and Bueno-De-Mesquita, {H. Bas} and Federico Canzian and Gabriele Capurso and Cavestro, {Giulia M.} and Chaffee, {Kari G.} and Chanock, {Stephen J.} and Cleary, {Sean P.} and Michelle Cotterchio and Lenka Foretova and Charles Fuchs and Niccola Funel and Maria Gazouli and Manal Hassan and Herman, {Joseph M.} and Ivana Holcatova and Holly, {Elizabeth A.} and Hoover, {Robert N.} and Hung, {Rayjean J.} and Vladimir Janout and Key, {Timothy J.} and Juozas Kupcinskas and Kurtz, {Robert C.} and Stefano Landi and Lingeng Lu and Ewa Malecka-Panas and Andrea Mambrini and Beatrice Mohelnikova-Duchonova and Neoptolemos, {John P.} and Oberg, {Ann L.} and Irene Orlow and Claudio Pasquali and Raffaele Pezzilli and Cosmeri Rizzato and Amethyst Saldia and Aldo Scarpa and Stolzenberg-Solomon, {Rachael Z.} and Oliver Strobel and Francesca Tavano and Vashist, {Yogesh K.} and Pavel Vodicka and Wolpin, {Brian M.} and Herbert Yu and Petersen, {Gloria M.} and Risch, {Harvey A.} and Klein, {Alison P.}",

note = "Funding Information: This work was supported by National Cancer Institute/US National Institutes of Health grant RO1 CA154823. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the US National Institutes of Health to the Johns Hopkins University, contract HHSN268201100011I. The IARC/Central Europe study was supported by a grant from the National Cancer Institute, US National Institutes of Health (R03 CA123546-02) and by grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3 and MH CZ-DRO-MMCI 00209805). The work at Johns Hopkins University was supported by National Cancer Institute grants P50 CA62924 and R01 CA97075. Additional support was provided by Susan Wojcicki and Dennis Troper. Funding Information: The Mayo Clinic Molecular Epidemiology of Pancreatic Cancer study is supported by the Mayo Clinic Specialized Programs of Research Excellence (SPORE) in Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by National Cancer Institute/US National Institutes of Health grant P30 CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation and the Society of the Memorial Sloan Kettering Cancer Center. The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC; grant 442302). R.E.N. is supported by an NHMRC Senior Research Fellowship (1060183). The University of California San Francisco (UCSF) pancreas study was supported by US National Institutes of Health/National Cancer Institute grants (R01 CA1009767 and R01 CA109767-S1) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California (CPIC); and the US Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries, under agreement U58 DP003862-01 awarded to the California Department of Public Health. The Yale (Connecticut) pancreas study is supported by US National Institutes of Health/National Cancer Institute grant 5R01 CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the Department of Public Health Human Investigation Committee of the state of Connecticut. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. Studies included in PANDoRA were partly funded by the Czech Science Foundation (P301/12/1734) and the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Ministry of Research, Science and Arts of Baden-W{\"u}rttemberg state (H.B.), the Heidelberger EPZ Pancobank (M.W. B{\"u}chler and team; T. Hackert, N.A. Giese, Ch. Tjaden, E. Soyka and M. Meinhardt; Heidelberger Stiftung Chirurgie and BMBF, grant 01GS08114), the BMBH (P. Schirmacher; BMBF grant 01EY1101), Dutch Cancer Society project grant 2012-5607 and the Academic Medical Center Foundation (M.F.B.), the “5x1000” voluntary contribution of the Italian government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54 and RC1303GA50), the Italian Association for Research on Cancer (A. Scarpa; AIRC 12182), the Italian Ministry of Research (A. Scarpa; FIRB-RBAP10AHJB), the Italian FIMP–Ministry of Health (A. Scarpa; CUP_J33G13000210001) and the National Institute for Health Research (NIHR) Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of F. Dijk and O. Busch (Academic Medical Center, Amsterdam). Publisher Copyright: {\textcopyright} 2015 Nature America, Inc. All rights reserved.",

year = "2015",

month = aug,

day = "30",

doi = "10.1038/ng.3341",

language = "English (US)",

volume = "47",

pages = "911--916",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

AU - Childs, Erica J.

AU - Mocci, Evelina

AU - Campa, Daniele

AU - Bracci, Paige M.

AU - Gallinger, Steven

AU - Goggins, Michael

AU - Li, Donghui

AU - Neale, Rachel E.

AU - Olson, Sara H.

AU - Scelo, Ghislaine

AU - Amundadottir, Laufey T.

AU - Bamlet, William R.

AU - Bijlsma, Maarten F.

AU - Blackford, Amanda

AU - Borges, Michael

AU - Brennan, Paul

AU - Brenner, Hermann

AU - Bueno-De-Mesquita, H. Bas

AU - Canzian, Federico

AU - Capurso, Gabriele

AU - Cavestro, Giulia M.

AU - Chaffee, Kari G.

AU - Chanock, Stephen J.

AU - Cleary, Sean P.

AU - Cotterchio, Michelle

AU - Foretova, Lenka

AU - Fuchs, Charles

AU - Funel, Niccola

AU - Gazouli, Maria

AU - Hassan, Manal

AU - Herman, Joseph M.

AU - Holcatova, Ivana

AU - Holly, Elizabeth A.

AU - Hoover, Robert N.

AU - Hung, Rayjean J.

AU - Janout, Vladimir

AU - Key, Timothy J.

AU - Kupcinskas, Juozas

AU - Kurtz, Robert C.

AU - Landi, Stefano

AU - Lu, Lingeng

AU - Malecka-Panas, Ewa

AU - Mambrini, Andrea

AU - Mohelnikova-Duchonova, Beatrice

AU - Neoptolemos, John P.

AU - Oberg, Ann L.

AU - Orlow, Irene

AU - Pasquali, Claudio

AU - Pezzilli, Raffaele

AU - Rizzato, Cosmeri

AU - Saldia, Amethyst

AU - Scarpa, Aldo

AU - Stolzenberg-Solomon, Rachael Z.

AU - Strobel, Oliver

AU - Tavano, Francesca

AU - Vashist, Yogesh K.

AU - Vodicka, Pavel

AU - Wolpin, Brian M.

AU - Yu, Herbert

AU - Petersen, Gloria M.

AU - Risch, Harvey A.

AU - Klein, Alison P.

N1 - Funding Information: This work was supported by National Cancer Institute/US National Institutes of Health grant RO1 CA154823. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the US National Institutes of Health to the Johns Hopkins University, contract HHSN268201100011I. The IARC/Central Europe study was supported by a grant from the National Cancer Institute, US National Institutes of Health (R03 CA123546-02) and by grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3 and MH CZ-DRO-MMCI 00209805). The work at Johns Hopkins University was supported by National Cancer Institute grants P50 CA62924 and R01 CA97075. Additional support was provided by Susan Wojcicki and Dennis Troper. Funding Information: The Mayo Clinic Molecular Epidemiology of Pancreatic Cancer study is supported by the Mayo Clinic Specialized Programs of Research Excellence (SPORE) in Pancreatic Cancer (P50 CA102701). The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by National Cancer Institute/US National Institutes of Health grant P30 CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation and the Society of the Memorial Sloan Kettering Cancer Center. The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC; grant 442302). R.E.N. is supported by an NHMRC Senior Research Fellowship (1060183). The University of California San Francisco (UCSF) pancreas study was supported by US National Institutes of Health/National Cancer Institute grants (R01 CA1009767 and R01 CA109767-S1) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California (CPIC); and the US Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries, under agreement U58 DP003862-01 awarded to the California Department of Public Health. The Yale (Connecticut) pancreas study is supported by US National Institutes of Health/National Cancer Institute grant 5R01 CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the Department of Public Health Human Investigation Committee of the state of Connecticut. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. Studies included in PANDoRA were partly funded by the Czech Science Foundation (P301/12/1734) and the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Ministry of Research, Science and Arts of Baden-Württemberg state (H.B.), the Heidelberger EPZ Pancobank (M.W. Büchler and team; T. Hackert, N.A. Giese, Ch. Tjaden, E. Soyka and M. Meinhardt; Heidelberger Stiftung Chirurgie and BMBF, grant 01GS08114), the BMBH (P. Schirmacher; BMBF grant 01EY1101), Dutch Cancer Society project grant 2012-5607 and the Academic Medical Center Foundation (M.F.B.), the “5x1000” voluntary contribution of the Italian government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54 and RC1303GA50), the Italian Association for Research on Cancer (A. Scarpa; AIRC 12182), the Italian Ministry of Research (A. Scarpa; FIRB-RBAP10AHJB), the Italian FIMP–Ministry of Health (A. Scarpa; CUP_J33G13000210001) and the National Institute for Health Research (NIHR) Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of F. Dijk and O. Busch (Academic Medical Center, Amsterdam). Publisher Copyright: © 2015 Nature America, Inc. All rights reserved.

PY - 2015/8/30

Y1 - 2015/8/30

N2 - Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased risk. To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 × 10-14), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 × 10-8) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 × 10-8). We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 × 10-9), a region with previous suggestive evidence in Han Chinese. We replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 (LINC-PINT), 16q23.1 (BCAR1) and 22q12.1 (ZNRF3). Our study identifies new loci associated with pancreatic cancer risk.

AB - Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased risk. To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 × 10-14), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 × 10-8) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 × 10-8). We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 × 10-9), a region with previous suggestive evidence in Han Chinese. We replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 (LINC-PINT), 16q23.1 (BCAR1) and 22q12.1 (ZNRF3). Our study identifies new loci associated with pancreatic cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=84938289037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938289037&partnerID=8YFLogxK

U2 - 10.1038/ng.3341

DO - 10.1038/ng.3341

M3 - Article

C2 - 26098869

AN - SCOPUS:84938289037

SN - 1061-4036

VL - 47

SP - 911

EP - 916

JO - Nature Genetics

JF - Nature Genetics

IS - 8

ER -

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this